Trump Administration Targets Germany's Drug Price Controls

The Trump Administration has taken a major step toward addressing a longstanding problem in the global pharmaceutical market: wealthy foreign governments benefiting from American medical innovation while using government price controls to pay artificially low prices for the medicines their citizens use.

On June 18, U.S. Trade Representative Jamieson Greer announced the initiation of a Section 301 investigation into Germany's pharmaceutical pricing practices. The investigation will examine whether Germany's policies unfairly suppress reimbursement for innovative medicines and force the United States to bear a disproportionate share of global pharmaceutical research and development costs.

The move follows growing support in Congress for stronger action against foreign pharmaceutical price controls. Earlier this month, 48 House Republicans, including Rep. Vern Buchanan (R-FL) and Rep. Jodey Arrington (R-TX), sent a letter urging the Administration to use trade enforcement tools to challenge foreign government policies that shift the cost of medical innovation onto American patients.

The Administration's action also advances goals reflected in the USTRx Act (H.R. 4780), legislation sponsored by Buchanan and Arrington that the Center for a Free Economy previously endorsed. As CFE noted when supporting the bill, foreign governments should not be allowed to impose price controls at home while relying on American patients and taxpayers to finance a disproportionate share of pharmaceutical innovation.

The Problem With Foreign Price Controls

Many developed countries use government price controls to limit what they pay for prescription drugs. While those policies help contain healthcare spending abroad, they also shift more of the cost of pharmaceutical research and development onto American consumers, employers, taxpayers, and healthcare programs.

The Trump Administration has increasingly treated this as both a healthcare and trade issue. President Trump's 2025 executive order directed federal agencies to confront foreign policies that suppress pharmaceutical prices below fair market value and force Americans to shoulder a disproportionate share of global research and development costs.

According to the congressional letter, more than 70 percent of patented pharmaceutical profits in OECD countries come from U.S. sales despite the United States accounting for only about one-third of OECD economic output. Lawmakers argue that foreign price controls have allowed wealthy countries to benefit from American innovation without contributing proportionately to its cost.

Germany Becomes the Focus

Germany has become a particular focus because of concerns that it may further expand pharmaceutical price controls and reimbursement restrictions.

In announcing the investigation, Ambassador Greer cited reports that Germany is pursuing additional measures to reduce spending on innovative medicines. He warned that such actions move in the wrong direction at a time when trading partners should be contributing more fairly to the development of lifesaving treatments.

The investigation will evaluate whether Germany's pricing practices, including discounts and rebate requirements imposed on innovative pharmaceutical products, constitute unreasonable or discriminatory policies that burden U.S. commerce.

Under Section 301 of the Trade Act of 1974, USTR has the authority to investigate foreign government practices that harm American economic interests and pursue corrective action when necessary.

Building on the U.S.-U.K. Agreement

The Administration views the investigation as part of a broader effort to push back against foreign pharmaceutical price controls.

In April, the United States and the United Kingdom announced a pharmaceutical pricing arrangement intended to increase British spending on innovative medicines. Administration officials have pointed to that agreement as evidence that trade negotiations can encourage trading partners to contribute more fairly to the cost of pharmaceutical innovation.

The approach closely aligns with the objectives of the USTRx Act. The legislation would strengthen the Administration's ability to challenge foreign pharmaceutical price controls through U.S. trade policy and encourage more equitable burden-sharing among wealthy nations.

The House Republican letter specifically praised the U.S.-U.K. agreement, arguing that it reduces the burden on Americans to finance pharmaceutical innovation for the rest of the world and demonstrates that trade negotiations can produce meaningful reforms. Germany now faces increasing pressure to pursue a similar path rather than deepen policies that suppress pharmaceutical spending.

CFE Takeaway

The Trump Administration's investigation into Germany's pharmaceutical pricing practices is an important step toward confronting foreign drug price controls that shift the cost of medical innovation onto Americans. The action also advances the goals of the USTRx Act (H.R. 4780), sponsored by Rep. Vern Buchanan (R-FL) and Rep. Jodey Arrington (R-TX), which CFE previously endorsed. Wealthy nations that benefit from breakthrough medicines should contribute more fairly to the research and development that makes those treatments possible rather than relying on government price controls that leave American patients and taxpayers carrying a disproportionate share of the burden.